BioCentury | Mar 24, 2021
Product Development

Akero to advance NASH therapy in patients with compensated cirrhosis following Phase IIa readout

While Akero’s NASH therapy did not lead to the same levels of efficacy in patients with compensated cirrhosis as it did in less severe patients, the company views the data as sufficient to move into...
BioCentury | Dec 12, 2020
Regulation

CHMP’s December opinions include restrictions for Veklury in COVID, support for Daiichi, Seagen breast cancer drugs

In its December opinions, EMA’s CHMP recommended a restriction for Gilead’s Veklury, specifying that COVID-19 patients should be on low- or high-flow oxygen or other non-invasive ventilation at the start of treatment.  The committee also...
BioCentury | Jul 1, 2020
Product Development

Histology data builds on growing confidence around Akero’s NASH candidate

Akero’s biopsy data is the positive news the NASH field needed after FDA declined to approve what would have been the first drug for the indication earlier this week. Akero Therapeutics Inc. (NASDAQ:AKRO) rose $8.45...
BioCentury | Jun 26, 2020
Distillery Therapeutics

Increasing PXR activity to treat acute kidney injury

DISEASE CATEGORY: Renal INDICATION: Renal damage Promoting the activity of the transcription factor PXR could treat acute kidney injury (AKI). PXR protein levels in renal tubular cells were lower in kidney biopsies from 20 AKI...
BioCentury | Apr 4, 2020
Finance

Pandemic upends norms for public fund-raising in election year

As the global COVID-19 pandemic continues to crater equity markets, buysiders are increasing their cash positions and companies are taking measures to delay any fund-raising activity to 2H20, when capital raises can hopefully be done...
BioCentury | Apr 1, 2020
Product Development

Akero reports positive Phase IIa data for NASH; pandemic delays expansion cohort

Akero gained $4.02 (23%) to $21.20 Tuesday, adding around $115 million in market cap, after reporting that its lead candidate AKR-001 met primary and secondary endpoints in the Phase IIa BALANCED study to treat non-alcoholic...
BioCentury | Sep 30, 2019
Company News

Sobi adding to U.S. presence, hematology pipeline via $915M Dova takeout

With the $915 million takeout of Dova Pharmaceuticals and a co-development deal with Sanofi in hemophilia, Sobi is continuing its push into the U.S. and strengthening its presence in hematology. Swedish Orphan Biovitrum AB (SSE:SOBI)...
BioCentury | Jun 28, 2019
Company News

June 27 Company Quick Takes: Zogenix soars; plus Gardasil, Darzalex, Soliris and more

Zogenix shares surge after agreement to resubmit Fintepla NDA Zogenix Inc. (NASDAQ:ZGNX) closed up $8.24 (21%) to $47.65 on Thursday after the company announced it had reached an agreement with FDA to resubmit its NDA...
BioCentury | Jun 20, 2019
Financial News

New listings push IPO pace ahead of last year’s

A spate of biotech IPOs this week in which five companies raised nearly $620 million helped push the biopharma sector’s total haul from NASDAQ listings ahead of 2018’s record pace. Of the five to price...
BioCentury | May 25, 2019
Financial News

New IPO filings include BridgeBio, Dermavant, Prevail, Atreca, Akero

In a week in which two biotechs went public and a third opted for a billion-dollar takeout instead of an IPO, five companies filed on Friday to list on NASDAQ in IPOs that could raise...
Items per page:
1 - 10 of 72